US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

27.78 -0.01 (-0.04%)
Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
News headline image
Expert Ratings for Amylyx Pharma ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
A Preview Of Amylyx Pharma's Earnings ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Biotech Stocks to Buy Before Drug Trials End ↗
Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains. 
Via InvestorPlace
News headline image
Why Shares of Amylyx Pharmaceuticals Were Up Monday ↗
The company got a bump from an analyst's upgrade. 
Via The Motley Fool
News headline image
4 Analysts Have This to Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
7 Analysts Have This to Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs ↗
Shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) jumped in early trading on Monday, after remaining broadly flat last week. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
What 7 Analyst Ratings Have To Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
Analyst Expectations for Amylyx Pharma's Future ↗
 
Via Benzinga
News headline image
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment ↗
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) conditional marketing authorization... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharma Earnings Preview ↗
 
Via Benzinga
News headline image
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics? ↗
Which of these red-hot biotech stocks is the better buy right now? 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat
News headline image
2 Supercharged Growth Stocks to Buy Right Now ↗
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
US Stock Futures Signal Strong Finish To Wobbly Week — But Analyst Still Sees Recession Risk On Horizon ↗
 
Via Benzinga
News headline image
Amylyx Blows Past Sales Expectations, Reports Unexpected Profit — Shares Rocket ↗
The company was expected to post another loss, but instead came in with a gain of 2 cents per share. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Biotechs That Might Get Bought Out in 2023 ↗
Biotech is expected to be a hotbed of mergers and acquisitions this year. 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >